SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amid an FDA crackdown and DOJ referral over its compounded GLP-1 weight-loss drugs, sparking a heated debate between investors concerned about regulatory risks and those who view the company as a disruptive force challenging big pharma for affordable healthcare.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is trending due to ongoing discussions around its Polkadot 2.0 rollout, which includes a pivotal shift to a capped 2.1 billion token supply and the Agile Coretime model designed to enhance network utility. While many express deep frustration over recent price performance, a strong bullish contingent highlights these fundamental upgrades and staking opportunities as a major re-rating catalyst attracting institutional interest.

WorldFinancial

World Liberty Financial (WLFI) is trending as a U.S. House investigation into its $500 million investment deal with a UAE royal ignites a polarized community debate over its political implications and financial integrity. While proponents view the scrutiny as a buying opportunity ahead of anticipated product launches, skeptics dismiss the Trump-linked crypto venture as a "scam," fueling conversations around crypto regulation and market intervention.

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical, Risk, Legal Exhibitions and Print & print-related. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity. The Risk segment provides customers with solutions and decision tools that combine public and industry specific content with advanced technology and analytics to assist them in evaluating and predicting risk and enhancing operational efficiency. The Legal segment is a global provider of legal, regulatory and business information and analytics that helps customers increase productivity, improve decision-making and outcomes and advance the rule of law around the world. The Exhibitions segment is an event business, enhancing the effect of face-to-face through data and digital tools. The Print & print-related segment consistent with financial information provided to the board. The company was founded by Albert Edward Reed in 1903 and is headquartered in London, the United Kingdom.

RELX Plc - ADR

RELX is a focal point of discussion as fears of AI disruption from new legal tools cause a sell-off, while a segment of the community views the dip as a prime opportunity to invest in its high-quality, data-moat business, emphasizing its strong AI integration and ongoing share buyback program.

Hyperliquid is a performant L1 optimized from the ground up. The vision is a fully onchain open financial system with user built applications interfacing with performant native components, all without compromising end user experience.   The Hyperliquid L1 is performant enough to operate an entire ecosystem of permissionless financial applications – every order, cancel, trade, and liquidation happens transparently on-chain with block latency &lt;1 second. The chain currently supports 100k orders / second.  The Hyperliquid L1 uses a custom consensus algorithm called HyperBFT which is heavily inspired by Hotstuff and its successors. Both the algorithm and networking stack are optimized from the ground up to support the L1.   The flagship native application is a fully onchain order book perpetuals exchange, the Hyperliquid DEX. Further developments include a native token standard, spot trading, permissionless liquidity, etc.

Hype

HYPE is trending as its Layer-1 decentralized exchange demonstrates strong resilience and outperformance amidst broader crypto market volatility, fueled by significant token buybacks from high trading volume and notable institutional interest including recent exchange listings. The community is actively discussing its potential to become a leading "House of All Finance," even as upcoming token unlocks introduce short-term market dynamics.

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

Pulse Biosciences Inc

Pulse Biosciences is trending due to its FDA Breakthrough Device Designation for the CellFX nsPFA Cardiac Surgery System and positive clinical data from first-in-human studies. The community is actively discussing the game-changing potential of its nanosecond Pulsed Field Ablation platform technology across multiple medical applications, reinforced by notable insider buying.

BlackRock Institutional Trust Company N.A. - iShares China Large-Cap ETF

iShares China Large-Cap ETF

FXI is actively discussed as investors weigh a significant trade surplus and recent policy support against concerns over manufacturing contraction and a struggling property sector. The community is watching for further clarity from ongoing US-China trade discussions and potential stimulus, which could drive a broader rally in Chinese equities.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health Inc. is trending strongly following its reaffirmed FY25 outlook and accelerating VEVYE prescription growth, driven by preferred formulary status and an expanded sales force. The community is buzzing with bullish sentiment, highlighting numerous analyst upgrades and the potential for a short squeeze as the company's eye-care portfolio is viewed as significantly undervalued and primed for explosive expansion.

GhostwareOS (GHOST) is the Full-Stack Privacy Layer of Solana — a next-generation AI-driven infrastructure for encrypted communication, anonymous identity management, and untraceable transactions. By combining advanced zero-knowledge protocols with autonomous AI routing, GhostwareOS allows users and developers to operate invisibly across Web3. It powers decentralized apps that demand true digital anonymity, scalable privacy, and zero metadata leakage — restoring control to users in an overexposed internet age.

Ghost

GHOST CRYPTO is trending as a high-potential privacy project on Solana, fueled by recent integrations like the Solflare wallet and ongoing discussions about its utility, low market cap, and upcoming revenue share. Community members are actively speculating on its decoupling from broader market trends and significant growth, viewing it as an early gem in the privacy narrative.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as its community actively builds momentum and anticipates the upcoming 4/20 cultural event, rallying around its core mission to support global cannabis legalization and integrate real-world utility, frequently promoting itself as "like Bitcoin but way higher." Community sentiment highlights a focus on consistency, patience, and a balanced approach to growth within its unique cannabis culture.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Spinnaker Trust Has $21.12 Million Stock Holdings in Ares Capital Corporation $ARCC

Spinnaker Trust boosted its stake in Ares Capital Corporation (NASDAQ:ARCC - Free Report) by 14.4% during the third quarter, according to the company in its most recent filing with the SEC. The fund...

Ares Capital (NASDAQ:ARCC) Stock Rating Lowered by Wall Street Zen

Wall Street Zen downgraded shares of Ares Capital from a "hold" rating to a "sell" rating in a research report on Saturday...

Wells Fargo & Company Has Lowered Expectations for Ares Capital (NASDAQ:ARCC) Stock Price

Wells Fargo & Company decreased their price target on shares of Ares Capital from $21.00 to $20.00 and set an "overweight" rating for the company in a research report on Thursday...

ARCC's Q4 Earnings Meet, Stock Up on Higher Total Investment Income

Ares Capital's Q4 core earnings match estimates as total investment income rises, offset by higher expenses. Shares climb 2.3% after the report.

Border to Coast Pensions Partnership Ltd Purchases 100,000 Shares of Ares Capital Corporation $ARCC

Border to Coast Pensions Partnership Ltd boosted its holdings in shares of Ares Capital Corporation (NASDAQ:ARCC - Free Report) by 5.3% during the third quarter, according to its most recent Form 13F...

Ares Capital (ARCC) Reports Q4 Earnings: What Key Metrics Have to Say

The headline numbers for Ares Capital (ARCC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ares Capital (ARCC) Matches Q4 Earnings Estimates

Ares Capital (ARCC) delivered earnings and revenue surprises of 0.00% and -0.38%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Is Ares Capital Stock Worth Owning Ahead of Q4 Earnings?

ARCC is set to post Q4 results, with a modest revenue growth forecast, flat EPS estimates and expense pressures as rate cuts weigh on sentiment.

Ares Capital Corporation Announces Tax Reporting Information for Calendar Year 2025

Ares Capital Corporation (Ares Capital or the Company) (NASDAQ: ARCC) announced today the tax treatment of the Companys 2025 common stock distributions (CUSIP #: 04010L103). Ordinary Income Per Share...

Wall Street Analysts Think Ares Capital (ARCC) Is a Good Investment: Is It?

The average brokerage recommendation (ABR) for Ares Capital (ARCC) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Ares Capital Corp is a traded fund invests in companies located in the United States and Canada with an EBITDA of USD 10 - 250 million. The fund targets companies operating in the fields of health care services, software & services, consumer durables & apparel, energy, food & beverage and retail. It provides financing in the form of debt and equity for mezzanine, buyouts, acquisitions, recapitalizations, restructurings, rescue financing, growth capital and general refinancing with an investment size ranging from USD 10 - 500 million. The fund acquires controlling Interest. It acts as lead investor and takes a seat on the board of directors.

Ares Capital Corp

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

ARCC
Ares Capital Corporation

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ARCC News

ARCCAres Capital Corporation